Esperion Therapeutics (NASDAQ:ESPR) had its price target upped by investment analysts at Chardan Capital from $20.00 to $75.00 in a research report issued to clients and investors on Wednesday. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Chardan Capital’s price objective suggests a potential upside of 27.88% from the company’s current price.
Other equities analysts also recently issued research reports about the company. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 price objective (up previously from $60.00) on shares of Esperion Therapeutics in a research report on Thursday, August 10th. Deutsche Bank set a $64.00 price objective on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Jefferies Group upgraded Esperion Therapeutics from a “hold” rating to a “buy” rating and reduced their price objective for the stock from $85.00 to $55.00 in a research report on Tuesday, August 8th. Northland Securities restated a “buy” rating and issued a $72.00 target price on shares of Esperion Therapeutics in a research report on Friday, November 10th. Finally, Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $60.15.
Esperion Therapeutics (ESPR) opened at $58.65 on Wednesday. Esperion Therapeutics has a 1 year low of $10.71 and a 1 year high of $65.20.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.07). During the same period in the previous year, the firm posted ($0.77) earnings per share. research analysts predict that Esperion Therapeutics will post -7.21 EPS for the current year.
A number of large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC raised its holdings in shares of Esperion Therapeutics by 69,371.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,863 shares of the biopharmaceutical company’s stock valued at $225,000 after buying an additional 4,856 shares during the period. Aperio Group LLC purchased a new stake in shares of Esperion Therapeutics in the 2nd quarter valued at $249,000. SG Americas Securities LLC raised its holdings in shares of Esperion Therapeutics by 74.5% in the 2nd quarter. SG Americas Securities LLC now owns 7,008 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 2,991 shares during the period. Voya Investment Management LLC raised its holdings in shares of Esperion Therapeutics by 12.7% in the 2nd quarter. Voya Investment Management LLC now owns 7,148 shares of the biopharmaceutical company’s stock valued at $331,000 after buying an additional 806 shares during the period. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in shares of Esperion Therapeutics in the 1st quarter valued at $385,000. Institutional investors own 92.27% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Esperion Therapeutics (ESPR) Given New $75.00 Price Target at Chardan Capital” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://ledgergazette.com/2017/12/06/esperion-therapeutics-espr-given-new-75-00-price-target-at-chardan-capital.html.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.